A型肉毒毒素轻链基因的克隆及其结构分析

以献报道的A型肉毒毒素基因全序列为标准,设计并合成一对引物,自肉毒梭菌基因组中扩增出肉毒毒素轻链基因片段,并将扩增产物与pGEM—T载体在体外连接,构建测序重组质粒,进行测序和基因结构分析。PCR扩增获得了产物为1 364bp的DNA片段,测序结果与DNA数据库对照检索分析证明,此基因片段与GenBank中的A型肉毒毒素LC基因的一致性达99．9％以上,可以认为克隆的基因为A型肉毒毒素LC基因。     

SREBP-1基因过表达促进人肾小管上皮细胞甘油三酯形成

目的 SREBP-1重组质粒转染人肾小管上皮细胞(HKC)检测SREBP-1基因表达和细胞内脂滴的关系。方法体外培养人肾小管上皮细胞并随机分为空白对照组、pcDNA3.1空质粒对照组和pcDNA3.1-SC1重组质粒转染组,采用阳离子脂质体法将SREBP-1特异性质粒pcDNA3.1-SC1及pcDNA3.1空质粒转染到细胞内并培养48小时,半定量RT-PCR和Westernblot分析目标基因表达丰度的变化,并采用油红O染色检测细胞内脂滴。结果 pcDNA3.1-SC1重组质粒转染的细胞内SREBP-1mRNA表达呈现明显升高,扩增条带积分光密度值分别是空白对照组和阴性对照组的6.158倍和4.194倍,SREBP-1蛋白也出现明显上调,条带积分光密度值为3.092±0.254。空白对照组和pcDNA3.1阴性对照组细胞内均未见有红染脂滴颗粒,而pcDNA3.1-SC1重组质粒转染组中出现了清晰的红染颗粒。结论 SREBP-1表达可增加人肾小管上皮细胞脂肪合成证实HKC细胞中SREBP-1表达和脂滴形成之间存在有直接关系。     

带Myc、His标签的SPAG4L真核表达载体的构建与表达

为了获得带有His、Myc 双标签的SPAG4L蛋白,建立能够稳定表达该蛋白的细胞系,本研究利用PCR技术从人睾丸cDNA中扩增SPAG4L开放阅读框,构建到pcDNA3.1(+)myc-his真核表达载体中进行测序和双酶切验证。将pcDNA3.1/myc-His(-)A/SPAG4L质粒和空白载体分别转染HeLa细胞,G418筛选后建立稳定转染细胞系。用Western blotting和免疫荧光技术对新建立的稳定转染细胞系进行检测。结果表明,成功扩增了SPAG4L基因,构建到pcDNA3.1/myc-His(-)A真核表达载体后,经酶切和测序验证所插入的SPAG4L序列完全正确;pcDNA3.1/myc-His(-)A/SPAG4L转染HeLa细胞后,经G418筛选后建立了稳定转染细胞系。Western blotting检测后发现,新建立的细胞系能够正确表达SPAG4L及其标签蛋白,进一步的免疫荧光实验发现,SPAG4L能够和内质网标签蛋白PDI共定位。研究结果所提供的稳定转染细胞系将为下一步进行免疫共沉淀和pull-down实验提供了有力的工具。     

病毒负性调节因子在内皮细胞稳定表达细胞株的建立

建立HIV-1的调节基因Nef基因在内皮细胞稳定表达的细胞株ECV304-Nef,为研究Nef对血管内皮细胞生物学活性的影响奠定试验基础。构建真核表达载体pcDNA3.1(+)-Nef,将其质粒和pcDNA3.1(+)质粒(阴性对照)分别转染血管内皮细胞ECV304,G418筛选。通过RT-PCR检测NefmRNA在细胞中的表达;细胞免疫荧光法检测Nef蛋白的表达及定位;Western blotting检测Nef蛋白的特异性表达,获得稳定表达的细胞株。构建的重组质粒pcDNA3.1(+)-Nef经BamHI和EcoRI双酶切鉴定,得到的片段大小与理论值相符,分别为载体的5400bp和目的基因的621bp。测序结果显示碱基序列与GenBank(登录号:K03455)序列相同。转染细胞经G418筛选后获得稳定表达Nef的ECV304细胞株,RT-PCR显示转染pcD-NA3.1(+)-Nef质粒的ECV304细胞出现621bp条带,对照组无目的条带出现;荧光显微镜下观察转染pcDNA3.1(+)-Nef质粒的ECV304细胞表达的Nef蛋白主要定位于细胞质中。Western blotting结果显示,转染pcDNA3.1(+)-Nef质粒的ECV304细胞约27kD处检测到目的条带,表明pcDNA3.1(+)-Nef表达正确。     

重组抗A型肉毒毒素人鼠嵌合单克隆抗体的瞬时表达及中和活性研究

为了制备重组抗A型肉毒毒素(botulinum neurotoxin A,BoNT/A)人鼠嵌合单克隆抗体并分析中和活性,以BoNT/A作为抗原筛选鼠源抗BoNT/A噬菌体单链抗体库,将筛选得到的鼠源抗BoNT/A特异性单链抗体的重链和轻链可变区分别克隆到pGP5KCγ和pGP5KCκ载体构建表达质粒。表达质粒共转染HEK-293EBNA1细胞,瞬时表达抗BoNT/A人鼠嵌合单克隆抗体(monoclonal antibody,mAb)。蛋白A亲和纯化mAb,分子排阻高效液相色谱(size exclusion high performance liquid chromatography,SEC-HPLC)分析mAb纯度,小鼠中和试验评价mAb中和活性。结果显示,经过筛选得到4个序列正确且各不相同的抗BoNT/A单链抗体。4个抗BoNT/A人鼠嵌合mAb表达质粒均构建成功并转染HEK-293EBNA1细胞,根据转染效率指示绿色荧光蛋白的表达推测,50%～62. 5%的细胞表达抗BoNT/A抗体。表达上清经过蛋白A亲和纯化,浓度均200μg/mL,单体纯度均90%。小鼠中和试验显示mA1、mA2、mA3和mA4单株抗体均不能完全中和4 LD_(50)的A型肉毒毒素,但从延迟小鼠生存时间可以得出4个抗体的中和活性为mA3mA2mA1mA4。mA1、mA2、mA4中任何一个抗体与mA3连用中和活性为80 LD_(50)/mg。本研究制备了4个具有不同程度中和活性的抗BoNT/A人鼠嵌合mAb,为A型肉毒神经毒素鸡尾酒疗法奠定了基础。     

pcDNA3.1-Canstatin-3Flag真核表达载体的构建及转染HepG2细胞中的表达

目的:构建pcDNA3.1-Canstatin-3Flag载体并稳定转染肝癌HepG2细胞,检测canstatin在mRNA水平的表达。方法:胎盘中提取总RNA,RT-PCR法获得canstatinDNA,克隆至pcDNA3.1(-)载体中,并测序,重组质粒pcDNA3.1-Canstatin-3Flag转染肝癌HepG2细胞,G418筛选出稳定转染细胞,RT-PCR检测canstatin mRNA表达。结果:1.成功构建出pcDNA3.1-Canstatin-3Flag重组质粒;2.获得稳定转染pcDNA3.1-Canstatin-3Flag的肝癌HepG2细胞;3.发现转染后的肝癌HepG2细胞canstatin在mRNA水平比未转染细胞有明显的增强。结论:获得了稳定转染pcDNA3.1-Canstatin-3Flag的肝癌HepG2细胞,为后期canstatin在肝癌中的研究提供了支持。     

HCV 5A基因在Hela细胞中的稳定表达及对细胞生长的抑制现象

应用PCR技术从含有HCV(Hepatitis C virus)全长开放阅读框的质粒pBRTM/HCV 1-3011中获得NS5A全长基因片断,利用基因重组技术将其克隆至真核表达载体pcDNA3.1(-)中.通过酶切、PCR及测序鉴定NS5A基因已正确插入到pcDNA3.1(-)中,再利用脂质体介导转染Hela细胞,48h后传代并利用pcDNA3.1(-)质粒上的neo抗性基因加入G-418进行筛选.大约两周后,获得稳定表达的细胞株.经RT-PCR及western blot验证,证实HCV的NS5A基因在Hela细胞中已经获得了表达.在培养条件完全一致的条件下,表达NS5A基因的Hela细胞与pcDNA3.1(-)转染的细胞相比,生长速度明显变慢,其倍增时间约为35-36h,比对照组细胞增加了约50%,而转染pcDNA3.1(-)的细胞的倍增时间与正常Hela细胞则无明显差别,都为23-24h.从而证明HCV的NS5A蛋白具有抑制Hela细胞生长的作用.     

A型肉毒毒素ELISA鉴别试验方法的建立

目的建立鉴定A型肉毒毒素的ELISA鉴别试验方法以替代传统的动物试验法。方法采用现代免疫学技术,制备马源性和兔源性抗A型肉毒毒素多克隆抗体,建立了双抗体夹心ELISA,并就此初步进行方法学验证。结果所建立的ELISA具有良好的特异性、灵敏度、精密度和耐用性,具有替代动物试验方法的良好前景。结论在进一步验证和确认之后,该方法有望正式成为可用于鉴定A型肉毒毒素的试验方法以替代动物试验法。     

肉毒毒素抑制剂的研究进展

肉毒毒素(BoNT)是目前已知的毒性最强的生物毒素,肉毒毒素中毒的抗毒素治疗只对未进入神经细胞的毒素有效,而对中毒时间较长、轻链已进入神经系统者无效。近10年来,随着肉毒毒素晶体结构的测定、中毒机理的深入研究,以及体外高通量评价模型的建立,对小分子肉毒毒素抑制剂的研究取得了显著进展。从肉毒毒素中毒机理、结构特征出发,简要综述了肉毒毒素抑制剂的研究进展。     

表达血管内皮生长因子-siRNA及双自杀基因yCDglyTK的联合基因载体构建及其应用研究

构建了新型联合基因载体pcDNA3.1(-)VEGF-siRNA/yCDglyTK,研究其在人胃癌细胞系SGC7901细胞中的表达和杀伤作用.构建靶向血管内皮生长因子(VEGF)的干扰质粒pGenesil-VEGF-siRNA,采用PCR法从中扩增siRNA表达框(含U6启动子),亚克隆至双自杀基因载体pcDNA3.1(-)CV-yCDglyTK,构建联合基因质粒pcDNA3.1(-)VEGF-siRNA/yCDglyTK;通过酶切、测序等鉴定重组质粒;以磷酸钙纳米颗粒为载体,将干扰质粒、双自杀基因质粒及联合基因质粒转染SGC7901细胞,RT-PCR、Western-blot验证目的基因表达;MTT法检测转染细胞对5-氟胞嘧啶(5-FC)的敏感性.结果表明:酶切及测序证实联合基因载体pcDNA3.1(-)VEGF-siRNA/yCDglyTK构建成功;SGC7901细胞转染联合基因质粒后,RT-PCR、Western-blot证实融合自杀基因表达,而VEGF基因表达下调;在前体药物5-FC作用下,转染联合基因组细胞存活率最低,与其他组比较有统计学差异.成功构建联合基因载体pcDNA3.1(-)VEGF-si...     

The light chain but not the heavy chain of botulinum A toxin inhibits exocytosis from permeabilized adrenal chromaffin cells

The heavy and light chains of botulinum A toxin were separated by anion exchange chromatography. Their intracellular actions were studied using bovine adrenal chromaffin cells permeabilized with streptolysin O. Purified light chain inhibited the Ca2+-stimulated [3H]noradrenaline release with a half-maximal effect at about 1.8 nM. The inhibition was incomplete. Heavy chain up to 28 nM was neither effective by itself nor did it enhance the inhibitory effect of light chain. It is concluded that the light chain of botulinum A toxin contains the functional domain responsible for the inhibition of exocytosis.     

Autoregulation in PC12 cells via P2Y receptors: Evidence for non-exocytotic nucleotide release from neuroendocrine cells

Nucleotides are released not only from neurons, but also from various other types of cells including fibroblasts, epithelial, endothelial and glial cells. While ATP release from non-neural cells is frequently Ca²⁺ independent and mostly non-vesicular, neuronal ATP release is generally believed to occur via exocytosis. To evaluate whether nucleotide release from neuroendocrine cells might involve a non-vesicular component, the autocrine/paracrine activation of P2Y₁₂ receptors was used as a biosensor for nucleotide release from PC12 cells. Expression of a plasmid coding for the botulinum toxin C1 light chain led to a decrease in syntaxin 1 detected in immunoblots of PC12 membranes. In parallel, spontaneous as well as depolarization-evoked release of previously incorporated [³H]noradrenaline from transfected cells was significantly reduced in comparison with the release from untransfected cells, thus indicating that exocytosis was impaired. In PC12 cells expressing the botulinum toxin C1 light chain, ADP reduced cyclic AMP synthesis to the same extent as in non-transfected cells. Likewise, the enhancement of cyclic AMP synthesis either due to the blockade of P2Y₁₂ receptors or due to the degradation of extracellular neucleotides by apyrase was not different between non-transfected and botulinum toxin C1 light chain expressing cells. However, the inhibition of cyclic AMP synthesis caused by depolarization-evoked release of endogenous nucleotides was either abolished or greatly reduced in cells expressing the botulinum toxin C1 light chain. Together, these results show that spontaneous nucleotide release from neuroendocrine cells may occur independently of vesicle exocytosis, whereas depolarization-evoked nucleotide release relies predominantly on exocytotic mechanisms.     

Mechanism of disorders in neurotrophic regulation of the level of striated skeletal muscle polarization by botulinum toxin

Muscle reinnervation was studied in experiments on rats given intramuscular injection of sublethal doses of botulinum toxin. It has been established that botulinum toxin not influencing the formation of functioning myoneural synapses leads to long-term persistence of depolarization of reinnervated muscle cells without changes in passive biophysical properties of their sarcoplasmatic membranes.     

The nucleotide and deduced amino acid sequences of EcoRI fragment containing the 5'-terminal region of Clostridium botulinum type E toxin gene cloned from Mashike, Iwanai and Otaru strains

Chromosomal DNAs were extracted from toxigenic three Clostridium botulinum type E strains isolated from food-borne botulism. After digestion by EcoRI, the fragments were cloned into Escherichia coli by using bacteriophage lambda gt11 and screened with monoclonal antibody recognizing the light chain component of botulinum type E toxin. The fragments (about 1 kbp size) cloned from each strain were recloned into a plasmid vector pUC118. The E. coli cells transformed with the recombinant plasmids produced 33 kDa protein with or without IPTG (isopropyl-beta-D-thiogalactopyranoside) which reacted with the monoclonal antibody. The nucleotide sequences of the cloned EcoRI fragments from the three type E strains were identical and contain the 5'-terminal region of the type E toxin gene. It was also found that there exist several highly homologous nucleotide sequences among the botulinum types A, C and E, and tetanus toxin genes in both translated and untranslated regions.     

Ca2(+)-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain

Permeabilisation of PC12 cells with digitonin allowed a direct study of the intracellular action of botulinum neurotoxin A, one of a group of dichain proteins produced by Clostridium botulinum that causes the fatal neuroparalytic condition, botulism. Release of [3H]noradrenaline from these permeabilised cells could be evoked by Ca2+ and this was inhibited specifically by the neurotoxin in a dose-dependent manner (half-maximal dose approximately 2 nM under the conditions used). Inclusion of the reducing agent dithiothreitol (up to 10 mM) had no effect on the level of inhibition. Moreover, electrophoretic analysis showed that this treatment of the toxin in the native state caused negligible reduction of inter-chain disulphide bonds. Toxin-induced blockade of neurotransmitter release was incomplete and could not be overcome by increased Ca2+ concentration (100 microM). The observed toxin-insensitivity of the release from intact PC12 cells must result from inefficient toxin uptake, relative to that in peripheral cholinergic neurones. Refolded light chain alone inhibited exocytosis to the same degree and with similar potency to that of the intact neurotoxin, an effect not altered by the heavy chain. This inhibitory activity of the light chain in PC12 cells accords with observations made in permeabilised chromaffin cells [(1989) J. Biol. Chem. 264, 10354-10360; (1989) FEBS Lett. 255, 391-394] but contrasts with invertebrate neurones, where intracellular injection of the same preparations of both chains were necessary for inhibition of quantal release of acetylcholine [(1988) Proc. Natl. Acad. Sci. USA 85, 4090-4094]. These collective findings may signify an interesting difference in the release process in such diverse systems or denote a dissimilarity in the transport or processing of the toxin when applied into intact neurones or cells permeabilised by detergent or streptolysin.     

人sTNFR1基因的克隆以及在NIH3T3细胞中的稳定表达

以He1a细胞的总RNA为模板,用RT—PCR方法扩增sTNFR1全编码区基因片段,构建含有目的片段的T载体克隆及真核表达载体pcDNA3．1（-）重组质粒亚克隆,将重组质粒和脂质体共同转染NIH3T3细胞系,G418筛选稳定转染细胞株．经核苷酸序列测序和酶切鉴定,成功构建了pcDNA3．1（-）-sTNFR1真核表达质粒,脂质体法建立了高效表达sTNFRI的稳定转染细胞系,并经RT—PCR和Western Blotting鉴定．人sTNFR1基因能在NIH3T3细胞系中稳定表达,为今后的研究打下了基础．     

Isolated light chains of botulinum neurotoxins inhibit exocytosis. Studies in digitonin-permeabilized chromaffin cells

The effects of botulinum neurotoxins or their light and heavy chain subunits were investigated in digitonin-permeabilized adrenal chromaffin cells. Because these cells are permeable to proteins, the toxin had direct access to the cell interior. Botulinum type A neurotoxin and its light chain subunit inhibited Ca2+-dependent catecholamine secretion in a dose-dependent manner. The heavy chain subunit had no effect. Inhibition required introduction of the neurotoxin or light chain into the cell and was not seen when intact cells were incubated with these proteins. The inhibition of secretion by type A neurotoxin and light chain was incomplete, the maximal response being 65%. The inhibition was not overcome by increasing Ca2+ concentrations. The action of the light chain was irreversible and rapid. Botulinum type E neurotoxin also inhibited secretion in a dose-dependent manner. Its potency was increased 30-fold following mild trypsinization, which nicked the single chain protein to the dichain form. In contrast to the results seen with types A and E, botulinum type B neurotoxin did not inhibit secretion, while its light chain totally abolished secretion. Trypsinization of the neurotoxin produced the dichain form, which did not inhibit secretion. Reduction of the trypsinized neurotoxin with dithiothreitol produced inhibition equivalent to that seen with the purified light chain subunit. Isolated type A heavy chain had no effect on the inhibitory action of type A or B light chains. The data demonstrate that the ability of botulinum neurotoxins to inhibit secretion is confined to the light chain region of these proteins. Furthermore, while the botulinum neurotoxin types A, B, and E have similar macrostructures, they are not identical with respect to their biological activities.     

Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay

A monoclonal antibody (BA11) has been produced against Clostridium botulinum type A neurotoxin by the fusion of myeloma cells (P3 NS1/1-Ag4-1) with spleen cells from BALB/c mice immunized with botulinum type A neurotoxoid. The antibody bound specifically to botulinum type A neurotoxin, showing no cross-reactivity with types B and E botulinum toxins or with any of several other bacterial toxins tested. The monoclonal antibody did not bind to botulinum type A neurotoxin which had been denatured with sodium dodecyl sulfate and bound only weakly to each of the separated heavy and light subunits of the neurotoxin, suggesting a conformational requirement for the antigenic determinant of the antibody. A sensitive immunoassay for C. botulinum type A toxin with monoclonal antibody BA11 in conjunction with an enzyme amplication system has been developed which allows detection of 5 to 10 mouse 50% lethal doses ml-1 of purified neurotoxin. The assay was equally sensitive when applied to the detection of crude toxin in food stuffs; the average value for the minimum level of detectable toxin in extracts of tinned salmon or corned beef was 9 +/- 3.1 mouse 50% lethal doses ml-1.     

Binding and cytotoxic effects of Clostridium botulinum type A, C1 and E toxins in primary neuron cultures from foetal mouse brains

Binding of purified Clostridium botulinum type A, C1 and E toxins to cultured cells was studied by an immunocytochemical method. Type A and C1 toxins bound strongly to neuron cultures prepared from brains of foetal mice, but binding of type E toxin was weak. None of the toxin types bound to the feeder layer, composed of non-neuronal cells. The heavy-chain component of the type C1 toxin bound to neurons, but the light chain component did not. Type C1 toxin also bound only to cell lines of neuronal origin. When type C1 toxin [final concentration 4 x 10(2) LD50 (10 ng) per well] was added to primary neuron cultures in 96-well plates, degeneration of neuronal processes and rounding of neuronal somas were observed, but type A and E toxins did not produce such changes. The binding and cytotoxic activities of type C1 toxin were blocked by heat treatment (80 degrees C for 30 min) or by preincubation of the toxin with polyclonal anti-C1 IgG and some of the monoclonal antibodies which neutralized the toxin activity in mice. In the neuronal processes treated with C1 toxin, many degenerated mitochondria, membranous dense bodies and vesicles were observed by electron microscopy; these ultrastructural changes were similar to those of Wallerian degeneration in vivo.     

Effects of botulinum toxin type D on secretion of tumor necrosis factor from human monocytes.

Botulinum toxins are potent neurotoxins which block the release of neurotransmitters. The effects of these toxins on hematopoietic cells, however, are unknown. Monocytes secrete a variety of polypeptide growth factors, including tumor necrosis factor (TNF). In the study reported here, the effects of botulinum toxin type D on the secretion of TNF from human monocytes were examined. The results demonstrate that botulinum toxin type D inhibits the release of TNF from monocytes activated by lipopolysaccharide (LPS) but not by 12-O-tetradecanoylphorbol-13-acetate. Botulinum toxin type D had no detectable effect on intracellular TNF levels in LPS-treated monocytes, indicating that the effects of this toxin involve the secretory process. This inhibitory effect of botulinum toxin type D on TNF secretion from LPS-treated monocytes was partially reversed by treatment with 12-O-tetradecanoylphorbol-13-acetate or introduction of guanosine 5'-[gamma-thio]triphosphate into these cells. The results demonstrate that TNF secretion is regulated by at least two distinct guanine nucleotide-binding proteins, one responsible for the activation of phospholipase C and another which acts as a substrate for botulinum toxin type D. ADP-ribosylation of monocyte membranes by botulinum toxin type D demonstrated the presence of three substrates with Mrs of 45,000, 21,000, and 17,000. While the role of these substrates in exocytosis is unknown, the results suggest that the Mr 21,000 substrate is involved in a process other than TNF secretion.